Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwang-ju, South Korea.
Int J Gynecol Cancer. 2010 Feb;20(2):288-93. doi: 10.1111/IGC.0b013e3181cd184c.
The aim of the study was to determine whether human papillomavirus (HPV) L1 capsid protein and the HPV genotype can predict the disease course as prognostic markers for cervical intraepithelial neoplasia 1 (CIN1).
Immunohistochemical staining was performed for HPV L1 capsid protein in 101 women who had been confirmed to have CIN1 by histologic examination and HPV high-risk infection by HPV genotyping. The disease course was analyzed by follow-up histologic examination according to the HPV L1 capsid protein and HPV genotype over a minimum of 12 months.
The CIN1 regressed spontaneously in 60.4% of the women; most cases of regression occurred within 1 year (90.9% of regression cases). The HPV L1 capsid protein-positive patients had a spontaneous regression rate of 72.7% (48/66) and a rate of persistent disease or progression to higher grade disease of 27.3% (18/66). The HPV L1 capsid protein-negative women had a regression rate of 37.1% (13/35) and a rate of persistent disease or progression of 62.9% (22/35; P < 0.001). The HPV-16-infected patients had a regression rate of 38.6% (17/44) and a rate of persistent disease or progression of 61.4% (27/44), whereas the non-HPV-16-infected patients had a regression rate of 77.2% (44/57) and a rate of persistent disease or progression of 22.8% (13/57; P < 0.001).
The HPV L1 protein expression is closely related to spontaneous disease regression, but HPV-16 infection is related to persistent disease or progression to high-grade lesions in patients with CIN1.
本研究旨在确定人乳头瘤病毒（HPV）L1 衣壳蛋白和 HPV 基因型是否可以作为宫颈上皮内瘤变 1（CIN1）的预后标志物来预测疾病进程。
对 101 例经组织学检查证实为 CIN1 且 HPV 高危型感染 HPV 基因分型的女性进行 HPV L1 衣壳蛋白的免疫组织化学染色。根据 HPV L1 衣壳蛋白和 HPV 基因型，通过至少 12 个月的随访组织学检查分析疾病进程。
CIN1 在 60.4%的女性中自发消退；大多数消退病例发生在 1 年内（90.9%的消退病例）。HPV L1 衣壳蛋白阳性患者的自发消退率为 72.7%（48/66），持续性疾病或进展为高级别疾病的发生率为 27.3%（18/66）。HPV L1 衣壳蛋白阴性的女性的消退率为 37.1%（13/35），持续性疾病或进展的发生率为 62.9%（22/35；P<0.001）。HPV-16 感染患者的消退率为 38.6%（17/44），持续性疾病或进展的发生率为 61.4%（27/44），而非 HPV-16 感染患者的消退率为 77.2%（44/57），持续性疾病或进展的发生率为 22.8%（13/57；P<0.001）。
HPV L1 蛋白表达与自发疾病消退密切相关，但 HPV-16 感染与 CIN1 患者持续性疾病或进展为高级别病变有关。
